Atrium Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its lead investigational therapy for the potential treatment of ...

Chinese cancer research is making its mark: new antibody-drug conjugates and bispecific antibodies improve survival in ...

Eli Lilly's olomorasib showed 62% tumor response in KRAS G12C-mutant lung cancer at ESMO 2026, but data comes from ...

Median progression-free survival was 7.6 months with the combination versus 5.4 with chemotherapy; results were presented at ...

BioNTech and Gilead redesigned the ROSETTA Breast-01 trial to pair pumitamig with Trodelvy, shifting from chemotherapy, with ...

Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% ...

A man accused of killing a North Carolina college student 14 years ago has been convicted of first-degree murder, rape and ...

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction.

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the ...

Jemperli for a type of locally advanced rectal cancer, and Hibsago as the first antisense treatment for chronic hepatitis B — while Roche expanded its antibody-drug conjugate partnership with China's ...

Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the3-27 European Society for Medical ...

This in-depth analysis delves into the explosive market buzz and hidden underlying jitters driving the latest 2024-2025 ...